Telltales podcast

Weekend Update - W2643

2026-10-25
0:00
8:43
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder

▶ Explore this week’s Tape — live, sortable, drill-down →

The Tape — W2643

Universe of 94 cashflow-memo names, snap dates 2026-10-17 → 2026-10-23. Composite is rank-sum percentile of FCF Yield + NTM Revenue Growth (higher = better balance). Banks and finance-book names shown separately.

Telltales Yield — Top 10

Telltales Yield — Bottom 10

This Week’s Reporters

Sector Medians

Debt / FCF Watch (highest leverage on TTM FCF)

Weekly Price Movement

Top 5 (week-over-week price)

Bottom 5 (week-over-week price)

Banks (shown separately — FCF metric not meaningful)

Finance-book — FCF not comparable

Customer-float / captive-finance / reserve businesses (IBKR broker float, KMX CarMax Auto Finance, PYPL customer funds, CRCL stablecoin reserves). The memo’s operating-FCF method overstates their FCF, so they are held off the ranked leaderboard pending the P&L-waterfall rebuild.

Data Gaps

90 of 91 ranked-eligible names ranked. 1 dropped for missing FCF yield or NTM revenue growth; 7 shown separately (banks + finance-book, FCF not comparable).

Source: cashflow-memo master_2026-10-23.csv. NTM growth from analyst-estimates consensus. Composite is a percentile rank, not a recommendation.

The Issue — This Week's Brief

The Cashflow Memo

Meta and Bloom Energy’s Third Quarters, Merck and Moderna’s Melanoma Data

Meta and Bloom Energy’s third quarters, the Merck and Moderna melanoma trial results, and Salesforce’s deal for Braze

The Telltales Weekend Update. Ava Cabot reports what the companies in the Cash Flow Memo disclosed this week and what is scheduled next. About 9 minutes.

Download the memo at telltales.us. Hunt, Jason, and Mike are back Wednesday on episode E2644.

Chapter markers

* Time | Segment

* 0:00 | Intro: what the episode covers

* 0:35 | Theme: Meta and Bloom Energy

* 3:00 | Deep dive: Merck and Moderna

* 4:55 | Rapid-fire: Salesforce, Netflix, Comcast, the earnings calendar

* 7:30 | Close

* 7:45 | Disclaimer

Full transcript

Intro

Ava: Welcome to the Telltales Weekend Update. I’m Ava Cabot.

Ava: This week, from the companies in the Cash Flow Memo: third-quarter results from Meta and Bloom Energy, the Phase 3 melanoma trial results from Merck and Moderna, Salesforce’s agreement to buy Braze, third-quarter results from Netflix and Comcast, and next week’s earnings calendar.

Ava: The show is produced entirely with AI tools, and the voice you’re hearing is AI-generated. The following conversation is intended for informational purposes only. You should always do your own work to determine if an investment is suitable for you.

Theme — Meta and Bloom Energy

Ava: Meta and Bloom Energy both reported their third quarters this week. Meta’s free cash flow and Bloom’s operating cash flow were both negative for the quarter[^8k-meta-q3-20261021][^8k-be-q3-20261022]. Meta first.

Ava: Meta reported on Wednesday. Per the earnings release, attached to an 8-K, revenue was about $65 billion, up 26% from a year earlier[^8k-meta-q3-20261021]. Cash from operations was about $33 billion, and capital expenditures, including principal payments on finance leases, were about $35 billion[^8k-meta-q3-20261021].

Ava: The release puts free cash flow for the quarter at negative $2.1 billion[^8k-meta-q3-20261021]. Costs in the quarter include a $9.9 billion charge for Meta’s agreement with state attorneys general to resolve litigation over teen mental health and social media[^8k-meta-q3-20261021].

Ava: For the fourth quarter, Meta guided revenue to $73 billion to $76 billion[^8k-meta-q3-20261021]. For this year’s capital expenditures, it now expects $135 billion to $145 billion, narrowed from $130 billion to $145 billion[^8k-meta-q3-20261021]. In the outlook section of the release, Meta’s chief financial officer wrote this about next year.

Meta’s chief financial officer, Q3 2026 earnings release (quoted): Looking beyond 2026, we are still developing our budget and capacity plans for next year, but we expect to continue investing aggressively to support both our core business and emerging AI initiatives.[^8k-meta-q3-20261021]

Ava: Separately, per the 8-K, Meta’s board declared a one-time dividend of one new non-voting Class C share for each outstanding Class A and Class B share[^8k-meta-classc-20261019]. The new class takes effect January 19, 2027, and the 8-K says the dividend will be paid no later than the fifth business day after that[^8k-meta-classc-20261019]. The release says that after the dividend is paid, Meta expects the Class A share price to reflect the effect of a two-for-one stock split[^8k-meta-q3-20261021].

Ava: Meta shares fell nearly 7% on Thursday, CNBC reports[^cnbc-meta-fcf-20261022]. The Cash Flow Memo dated October 19, page 4, shows Meta’s free cash flow at negative $17 billion, a figure that predates this report[^memo-meta-20261019]. Next, Bloom Energy.

Ava: Bloom Energy reported on Thursday. Per the earnings release, attached to an 8-K, revenue was about $1.2 billion, up 138% from a year earlier[^8k-be-q3-20261022]. Bloom raised its full-year revenue guidance to $4.4 billion to $4.6 billion[^8k-be-q3-20261022].

Ava: The cash flow statement in the release shows $27 million of cash used in operating activities in the quarter, against $226 million of cash provided in the second quarter[^8k-be-q3-20261022]. Purchases of property, plant and equipment were about $150 million[^8k-be-q3-20261022].

Ava: Bloom shares fell 11% on Friday, Investopedia reports[^invest-be-drop-20261023]. Next, Merck and Moderna.

Deep dive — Merck and Moderna

Ava: Merck and Moderna, both on page 15 of the memo. On Thursday, the two companies released detailed results from INTerpath-001, the Phase 3 trial of intismeran autogene, their investigational mRNA-based individualized neoantigen therapy, given with Merck’s Keytruda after surgery in stage IIB to IV melanoma, per their joint release[^pr-mrk-mrna-interpath-20261022]. CNBC reports the companies released the results after partial data leaked on social media earlier that day[^cnbc-mrna-results-20261023].

Ava: At the primary analysis, after a median follow-up of about 25 months, intismeran with Keytruda reduced the risk of recurrence or death by 42%, against Keytruda alone, per the release[^pr-mrk-mrna-interpath-20261022]. It reduced the risk of distant metastasis or death by 38%[^pr-mrk-mrna-interpath-20261022].

Ava: The release says that in the first six months, the combination’s effect was comparable with Keytruda alone[^pr-mrk-mrna-interpath-20261022]. From six months on, following the immunization regimen, a pre-specified sensitivity analysis showed a 58% reduction in the risk of recurrence or death[^pr-mrk-mrna-interpath-20261022].

Ava: Per the release, overall survival data are not yet mature, and the safety profile was generally consistent with earlier studies of the combination, with no new safety signals[^pr-mrk-mrna-interpath-20261022]. The results are scheduled for presentation at the European Society for Medical Oncology Congress and have been accepted for publication in The New England Journal of Medicine[^pr-mrk-mrna-interpath-20261022]. The companies said they are engaging with regulatory authorities[^pr-mrk-mrna-interpath-20261022].

Ava: In an interview before the results, Moderna chief executive Stéphane Bancel told CNBC the company is finishing a filing with regulators as it aims to get the drug fully approved next year[^cnbc-mrna-results-20261023].

Ava: CNBC reports that Moderna shares fell as much as 25% on Thursday before regaining some ground[^cnbc-mrna-leak-20261022]. The Cash Flow Memo dated October 19 has Merck at 23 times free cash flow, and shows Moderna’s free cash flow at negative $2.8 billion, with no multiple[^memo-mrk-mrna-20261019].

Ava: Merck reports its third quarter on Thursday, October 29[^earn-mrk], and Moderna reports on Friday, November 6[^earn-mrna]. On to the rapid-fire.

Rapid-fire

Ava: Salesforce. On Tuesday, it announced a definitive agreement to acquire Braze, a customer engagement software company, for about $5.7 billion in enterprise value, per the release attached to an…



This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com

Fler avsnitt från "Telltales"